Valuation: CSL Limited

Market Cap 46.81B 40.56B 38B 34.66B 65.16B 4,465B 66.16B 447B 175B 2,235B 176B 172B 7,454B P/E 2026 *
-52.4x
P/E 2027 * 32.6x
Enterprise Value 55.52B 48.11B 45.07B 41.11B 77.29B 5,296B 78.48B 530B 207B 2,652B 208B 204B 8,842B EV / Sales 2026 *
3.61x
EV / Sales 2027 * 3.51x
Free-Float
99.3%
Yield 2026 *
2.92%
Yield 2027 * 2.99%
1 day+0.08%
1 week+7.46%
Current month+12.50%
1 month+12.65%
3 months+37.41%
6 months-15.30%
Current year-19.81%
1 week 130.8
Extreme 130.8
139.03
1 month 113.75
Extreme 113.75
139.03
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
273.45
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 10/02/2026
Director of Finance/CFO 52 06/10/2025
Chief Operating Officer - 30/04/2025
Director TitleAgeSince
Director/Board Member 72 16/10/2018
Director/Board Member 70 01/02/2011
Director/Board Member 71 08/12/2019
Date Insider Type Main position Quantity % Market Cap.
23/02/26 Free

Director

263 0.0001%
23/02/26 Free 512 0.0001%
19/02/26 Fiscal year

Director

183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+0.08%+7.46%-47.52%-47.97% 46.77B
-0.23%+3.33%+42.69%-1.76% 79.58B
-3.73%+4.95%-2.38%+25.77% 52.73B
-1.95%-3.23%+18.58%+170.03% 49.77B
+1.60%-0.08%+60.15%-24.30% 30.13B
-0.36%+0.67%+47.78%+84.86% 24.54B
+4.94%+13.46%+148.74%-36.17% 24.18B
0.00%+10.21%+6.23%+188.24% 21.2B
+1.19%+3.11%+72.21%+167.96% 16.36B
-3.05%+18.95%-4.01%+768.95% 16.14B
Average -0.20%+4.06%+34.25%+129.56% 36.14B
Weighted average by Cap. -0.54%+3.84%+27.13%+74.89%

Financials

2026 *2027 *
Net sales 15.38B 13.33B 12.49B 11.39B 21.41B 1,467B 21.74B 147B 57.4B 735B 57.75B 56.49B 2,449B 15.59B 13.51B 12.65B 11.54B 21.7B 1,487B 22.03B 149B 58.18B 744B 58.53B 57.26B 2,482B
Net income -967M -838M -785M -716M -1.35B -92.2B -1.37B -9.23B -3.61B -46.17B -3.63B -3.55B -154B 1.18B 1.03B 962M 877M 1.65B 113B 1.67B 11.31B 4.42B 56.57B 4.45B 4.35B 189B
Net Debt 8.71B 7.55B 7.07B 6.45B 12.13B 831B 12.32B 83.21B 32.52B 416B 32.72B 32.01B 1,388B 7.98B 6.91B 6.48B 5.91B 11.1B 761B 11.27B 76.16B 29.77B 381B 29.95B 29.3B 1,270B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
12/08/26 A$138.44 +0.08% 1,043,685
11/08/26 A$138.33 +2.87% 1,152,737
10/08/26 A$134.47 +1.72% 837,360
07/08/26 A$132.19 -0.13% 779,357
06/08/26 A$132.36 +1.30% 1,125,931
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
97.95USD
Average target price
97.30USD
Spread / Average Target
-0.66%

Quarterly revenue - Rate of surprise